BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37141843)

  • 1. Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation.
    Dertschnig S; Passweg J; Bucher C; Medinger M; Tzankov A
    Cell Immunol; 2023 Jul; 388-389():104719. PubMed ID: 37141843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
    Dertschnig S; Gergely P; Finke J; Schanz U; Holler E; Holtick U; Socié G; Medinger M; Passweg J; Teshima T; Stylianou C; Oehen S; Heim D; Bucher C
    Transplant Cell Ther; 2023 Jan; 29(1):41.e1-41.e9. PubMed ID: 36343893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
    Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
    Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission.
    Tian L; Wu Y; Choi HJ; Sui X; Li X; Sofi MH; Kassir MF; Chen X; Mehrotra S; Ogretmen B; Yu XZ
    Cell Mol Immunol; 2022 Nov; 19(11):1235-1250. PubMed ID: 36071219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
    Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
    Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation.
    Ji SQ; Chen HR; Xun CQ; Wang HX; Pan SP; Xiao MH
    Clin Transplant; 2001 Oct; 15(5):317-23. PubMed ID: 11678957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
    Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
    Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
    Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
    Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
    Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
    Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation.
    Miyata M; Matsuki E; Ichikawa K; Takehara T; Hosokawa Y; Sekiguchi E; Peltier D; Reddy P; Ishizawa K; Watanabe M; Toubai T
    Blood Adv; 2023 Nov; 7(22):6936-6948. PubMed ID: 37748044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
    Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
    Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
    Mathioudaki A; Wang X; Sedloev D; Huth R; Kamal A; Hundemer M; Liu Y; Vasileiou S; Lulla P; Müller-Tidow C; Dreger P; Luft T; Sauer T; Schmitt M; Zaugg JB; Pabst C
    Blood; 2024 Mar; 143(13):1269-1281. PubMed ID: 38197505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.